Brief: Harrow Closes Acquisition Of U.S. Rights To Ilevro, Nevanac, Vigamox, Maxidex, Triesence

Harrow

23/01/2023 12:09

Jan 23 (Reuters) - Harrow Health Inc  HROW.O :
    * HARROW CLOSES ACQUISITION OF U.S. RIGHTS TO ILEVRO®,
NEVANAC®,
VIGAMOX®, MAXIDEX®, AND TRIESENCE® AND WILL BEGIN RECEIVING NET
PROFIT PAYMENTS FOR ACQUIRED PRODUCTS
    * HARROW HEALTH INC - EXPECTS PRODUCTS TO BE IMMEDIATELY
FINANCIALLY ACCRETIVE AND REAFFIRMS 2023 GUIDANCE OF $135
MILLION TO $143 MILLION IN NET REVENUES
    * HARROW HEALTH - BELIEVES BOTH NET REVENUES AND ADJUSTED
EBITDA
SHOULD GROW FURTHER DURING 2024 AND FOR AT LEAST THREE TO FIVE
YEARS THEREAFTER

Source text for Eikon:  ID:nBwby4Vha 
Further company coverage:  HROW.O 
 ((Reuters.Briefs@thomsonreuters.com;))